Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

THE PATH-2 Study is a trial of platelet rich plasma (PRP) as a non-surgical treatment for Achilles tendon rupture. PRP is blood plasma containing a high concentration of platelets, specialised blood cells involved in wound repair. Eligible patients are randomised to receive standard non-operative care, or standard care plus PRP injection. Our primary outcome is an objective test of ankle function conducted at 6 months after treatment by a blinded physiotherapist assessor. This is the first large double-blinded randomised controlled trial of PRP in tendons.

In September 2017 the PATH-2 Study reached its target of 230 participants, recruited at outpatient clinics in 18 hospitals in England and Wales. PATH-2 is funded by EME, a partnership of the National Institute for Health Research and the Medical Research Council (EME reference 12/206/30).

For more information visit https://path2.octru.ox.ac.uk/ or contact the team at path-2.study@ndorms.ox.ac.uk.

Similar stories

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!

OCTRU

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!

OCTRU

The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.